<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064051</url>
  </required_header>
  <id_info>
    <org_study_id>VION-CLI-031</org_study_id>
    <secondary_id>CDR0000306461</secondary_id>
    <nct_id>NCT00064051</nct_id>
  </id_info>
  <brief_title>3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of Triapine in Combination With Gemcitabine in Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by&#xD;
      blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more&#xD;
      cancer cells by making them more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine together with 3-AP works&#xD;
      in treating patients with unresectable or metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate (partial and complete response) in patients with&#xD;
           unresectable or metastatic pancreatic cancer treated with 3-AP and gemcitabine.&#xD;
&#xD;
        -  Determine the progression-free interval and survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the safety and feasibility of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Stage I: Patients receive 3-AP IV over 4 hours and gemcitabine IV over 30 minutes on&#xD;
           days 1, 8, and 15. Treatment repeats every 4 weeks for up to 12 courses in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Stage II: Patients receive a higher dose of 3-AP IV continuously over 24 hours on days&#xD;
           1, 8, and 15. Within 1 hour of completing 3-AP administration, patients receive&#xD;
           gemcitabine IV over 30 minutes on days 2, 9, and 16. Treatment repeats every 4 weeks for&#xD;
           up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1 month, every 2 months for 6 months, and then every 3 months for 18&#xD;
      months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50-95 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (partial and complete response) as assessed by RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and feasibility</measure>
  </secondary_outcome>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic cancer&#xD;
&#xD;
               -  Unresectable or metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Outside prior radiation ports OR within prior radiation port if evidence of&#xD;
                  disease progression after radiotherapy&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN in the&#xD;
             presence of liver metastases)&#xD;
&#xD;
          -  Chronic viral hepatitis allowed&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No uncontrolled coronary artery disease&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No dyspnea at rest&#xD;
&#xD;
          -  No dependence on supplemental oxygen&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy except any of the following:&#xD;
&#xD;
               -  Carcinoma in situ of the cervix treated with cone biopsy or resection&#xD;
&#xD;
               -  Nonmetastatic basal cell or squamous cell skin cancer&#xD;
&#xD;
               -  Any stage I malignancy curatively resected more than 5 years ago&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No known or suspected glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
          -  No other concurrent life threatening illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior vaccines, antibodies, cytokines, or small molecule cell signaling inhibitors&#xD;
             allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy for unresectable or metastatic pancreatic cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 weeks since prior surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 weeks since prior noncytotoxic treatment regimens and objective evidence&#xD;
             of progressive disease&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Oncology Hematology Consultants</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center at Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital N.H.S. Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

